Search Results - yon+ebright

7 Results Sort By:
Treatments for tuberculosis and non-tuberculous mycobacterial infections: dual-targeted rifamycin-AAP conjugates (RifaAAPs)
collapse; } ​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that...
Published: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: DUAL-TARGETED RNA POLYMERASE INHIBITORS (BENZOXAZINO-RIFAAAPS
​ Invention Summary: RifaAAPs are novel dual-targeted, low-resistance-emergence, orally-available compounds for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi-drug-resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that RifaAAPs comprise...
Published: 4/7/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Chih-Tsung Lin
Keywords(s): Antibacterial
Category(s): Technology Classifications > Infectious Disease, Technology Classifications > Healthcare & Life Sciences
ANTIBACTERIAL AGENTS: CO-SOLVENT-FREE, SURFACTANT-FREE FORMULATIONS OF PYRONINS
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 4/7/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
ANTIBACTERIAL AGENTS: O-ALKYL-DEUTERATED PYRONINS (PYS) AND ARYL PYRONINS (APYS)
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 4/7/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Treatments for drug-susceptible and drug-resistant bacterial infections: arylmyxopyronins (APYs)
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 4/7/2025   |   Inventor(s): Richard Ebright, Yon Ebright
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Infectious Disease
Therapeutics for Drug-Resistant Bacterial Infections - Myxopyronins
​ Invention Summary: APYs are novel, orally available compounds for treatment of infections caused by Gram-positive bacterial pathogens, fastidious Gram-negative bacterial pathogens, and some non-fastidious Gram-negative bacterial pathogens--including drug-resistant and multi-drug-resistant (MDR) strains. Our researchers have indicated...
Published: 4/7/2025   |   Inventor(s): Richard Ebright, Juan Shen, James Bacci, William Solvible, Christopher Self, Gary Olson, Yon Ebright, Anne-Cecile Hiebel
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics
Treatments for tuberculosis and non-tuberculous mycobacterial infections: N-aroyl-N-aryl-phenylalaninamides (AAPs)
​ Invention Summary: AAPs are novel orally available compounds for treatment for treatment of tuberculosis (TB) and non-tuberculous mycobacterial (NTM) infections--including drug-resistant, multi‑drug‑resistant (MDR), and extensively-drug-resistant (XDR) strains. Researchers indicate that AAPs potently inhibit mycobacterial RNA polymerase...
Published: 1/31/2025   |   Inventor(s): Richard Ebright, Yon Ebright, Soma Mandal
Keywords(s): Antibacterial
Category(s): Technology Classifications > Healthcare & Life Sciences, Technology Classifications > Therapeutics